Mechanism of Antimicrobial Action
The target of oxazolidinones is bacterial protein synthesis, specifically ribosomal function. Linezolid has a specific binding site: it binds to the P-site of the 50S subunit of the bacterial ribosome. As a result of this interaction, the earliest stage of translation is blocked—the formation of the initiation complex consisting of the ribosome and fMet-tRNA.
This mechanism has immense clinical significance. Because the binding site is completely unique, bacteria do not exhibit cross-resistance between oxazolidinones and other known protein synthesis inhibitors. The drug retains efficacy where macrolides, aminoglycosides, tetracyclines, lincosamides, and chloramphenicol fail. Resistance to linezolid develops extremely slowly and is associated with mutations in the 23S ribosomal RNA.
Spectrum of Activity and Type of Action
The main spectrum of activity covers Gram-positive flora. The drug serves as a reserve agent for treating infections caused by multiresistant strains:
- MRSA (methicillin-resistant Staphylococcus aureus);
- Penicillin-resistant streptococci;
- VRE (vancomycin-resistant enterococci and staphylococci).
Regarding the type of antimicrobial action, linezolid is primarily bacteriostatic—it halts bacterial growth and reproduction. However, there are important exceptions to this rule. The drug exhibits bactericidal activity (killing the cell) against anaerobic flora (Bacteroides fragilis, Clostridium perfringens) and certain streptococci (S. pneumoniae, S. pyogenes).
Pharmacokinetics and Indications
The drug features absolute bioavailability (100%), meaning it is absorbed completely when taken orally. This allows for both intravenous and oral administration with equal efficacy. The standard dosing regimen is every 12 hours.
Oxazolidinones are characterized by high tissue penetration. They achieve therapeutic concentrations in virtually all tissues and body fluids, including the skin, lungs, heart, central nervous system (CNS), bones, and synovial fluid.
Main indications include:
- Community-acquired and hospital-acquired pneumonia (important: if Gram-negative flora is suspected, combination therapy with other antibiotics is mandatory).
- Skin and soft tissue infections.
- Any infections caused by vancomycin-resistant enterococci.
Adverse Effects and Drug Interactions
Despite high efficacy, therapy requires careful monitoring due to a wide range of adverse reactions:
- Blood system: Reversible bone marrow suppression may occur, manifesting as thrombocytopenia, anemia, leukopenia, or pancytopenia.
- GI tract: Dyspeptic disorders (nausea, diarrhea), taste alterations, and specific tongue discoloration.
- Nervous system: Headache. Prolonged courses (exceeding 8 weeks) increase the risk of peripheral neuropathy and optic neuropathy.
- Other: Skin rash and metabolic disorders (lactic acidosis).
A pharmacological feature of linezolid is that it acts as a reversible non-selective monoamine oxidase inhibitor (MAOI). This creates serious clinical risks when interacting with other drugs. Combining it with adrenomimetics (epinephrine, dopamine) or serotonin reuptake inhibitors can lead to severe complications: tachycardia, severe headache, hypertensive crisis, and the life-threatening condition known as serotonin syndrome.